Bortezomib/ciprofloxacin/tocilizumab

Abstract

Various toxicities and lack of efficacy with an off label treatment: 2 case reports In a retrospective study of 60 patients with histological diagnosis of allergic tubulointerstitial nephritis from January 2009 to November 2020, two women were described, of whom a 51-year-old woman developed posterior reversible encephalopathy syndrome (PRES) syndrome and acute pyelonephritis during treatment with bortezomib, and an 82-year-old woman developed allergic tubulointerstitial nephritis during treatment with ciprofloxacin, and exhibited lack of efficacy with an off label treatment with tocilizumab and unspecified steroids, while being treated for COVID-19 nosocomial pneumonia [routes, dosages, duration of treatments to reactions onsets not stated; not all indications stated]. The 51-year-old woman, who had large B-cell lymphoma and allergic tubulointerstitial nephritis, had been receiving bortezomib. She was admitted due to acute pyelonephritis and PRES syndrome secondary to first dose of bortezomib. Subsequently, she developed COVID-19 nosocomial pneumonia and acute pancreatitis. Then, she was treated with unspecified corticosteroids and unspecified broad spectrum antibacterials [antibiotics]. However, she died due to abdominal refractory septic shock. The 82-year-old woman had been receiving ciprofloxacin. She developed acute kidney injury due to acute allergic tubulointerstitial nephritis associated with ciprofloxacin. Later, she developed severe COVID-19 nosocomial pneumonia. Thus, she received ventilatory support, off label tocilizumab and off label unspecified high-dose steroids therapy. Despite these treatments, she died [exact cause of death not stated].